Tag Archives: Pfizer

Financial Daily Dose 8.25.2020 | Top Story: U.S. and China Resume Trade Talks Over Phase One Status

BY: Michael D. Reif | August 25, 2020

Despite an earlier White House promise to postpone, American and Chinese trade negotiators met via videoconference on Monday to discuss “the status of the trade deal both nations signed in January, a pact that continues to open up some commerce between the world’s largest economies even as the bilateral relationship deteriorates in other areas” – … Continue reading

Financial Daily Dose 7.29.2019 | Top Story: Pfizer and Mylan Join Forces to Create Generics Powerhouse

BY: Michael D. Reif | July 29, 2019

Drug giants Pfizer and Mylan have inked a deal that will merge the former’s off-patent drugs with the latter’s generics business, a tie-up that creates a mammoth global seller of lower-priced medicines – WSJ and Bloomberg and NYTimes Friday’s GDP report showed US economic growth slowing to 2.1% in Q2, as higher consumer spending helped … Continue reading

Your Daily Dose of Financial News

BY: Michael D. Reif | October 11, 2017

The Peltz/P&G drama continues, with the company suggesting that Trian has lost its bid for a Board seat and the fund arguing that it disagrees with the company’s counting of the ballots – WSJ and NYTimes Pharma giant Pfizer is considering a new future for its consumer health care division (think Advil, Centrum, ChapStick, etc.) … Continue reading

Your daily dose of financial news

BY: Michael D. Reif | August 22, 2016

Pfizer’s reportedly reached an agreement to purchase Medivation—a biotech firm known for its prostate-cancer drug Xtandi—in what’s anticipated to be a $14 billion deal – WSJ and Bloomberg Valeant’s hiring Zoetis’ Paul Herendeen as its new CFO as part of a continued effort to get back on track under the watchful eye of Bill Ackman … Continue reading

Your daily dose of financial news

BY: Michael D. Reif | May 17, 2016

Gannet’s still after Tribune Publishing, and it’s upped its ante after Tribune “resoundingly rejected” early overtures – NYTimes The Journal walks us through the fall of the Laplanche empire at Lending Club with a blow-by-blow of his last days on the job – WSJ Big High Court securities news yesterday, as the Supremes unanimously held … Continue reading

Your daily dose of financial news

BY: Michael D. Reif | April 6, 2016

Talk about a regulation with teeth. Within days of the Treasury Department announcing new rules meant to discourage corporate tax inversion deals, Pfizer and Allergan announced they were scrapping their planned $152 billion merger – NYTimes and WSJ and Bloomberg Here’s the latest on the much-buzzed-about and controversial Labor Department fiduciary duty regulations for financial … Continue reading

Your daily dose of financial news

BY: Michael D. Reif | November 25, 2015

A groundbreaking move by Calpers—California’s state pension fund—to disclose how much money it’s made from and paid to private equity funds ($24.2 billion and $3.4 billion, respectively, since 1990) may help pave the way for increased transparency in the PE world – NYTimes and Bloomberg I suppose a $160+ billion deal merits some staying power.  … Continue reading

Your daily dose of financial news

BY: Michael D. Reif | November 24, 2015

The Pfizer/Allergan deal continues to dominate the financial world, with Pfizer’s CEO defending the merger and Washington searching for ways to reform the corporate tax code and prevent future tax-motivated corporate inversions – NYTimes All is not little yellow smiley faces at Yahoo, which finds itself mired in a “crisis of morale” as CEO Marissa … Continue reading

Your daily dose of financial news

BY: Michael D. Reif | November 23, 2015

Clocking in at an as-promised $150 billion, the Pfizer/Allergan merger is a done deal, marking one of the biggest ever takeovers in the health care industry.  As mentioned here last week, the deal finalization comes on the heels of the Treasury and IRS announcing new rules aimed at eliminating the tax benefits associated with deals … Continue reading

Your daily dose of financial news

BY: Michael D. Reif | October 29, 2015

As largely expected, the Fed made no moves on interest rates yesterday on the heels of its policy-making committee meeting, but Dr. Yellen took pains to stress the strength of the US economy and the likelihood that it will, seriously, bump rates in its final meeting of 2015 – NYTimes and WSJ Drug maker titans … Continue reading